NeuroGen Pharma Launches Commercial Supply of Ajovy in Mainland China – CGRP‑Targeted Monthly/Quarterly Migraine Prevention Therapy Reaches First Patients After NRDL Inclusion

Fineline Cube
5 Min Read
Summarize with AI

NeuroGen Pharma announced the commencement of clinical supply of Ajovy (fremanezumab injection), an innovative CGRP‑targeted therapy it has introduced for the preventive treatment of migraine – completing a rapid arc from licensing to patient access that began with the drug’s introduction into the Guangdong‑Hong Kong‑Macao Greater Bay Area and culminated in National Reimbursement Drug List (NRDL) inclusion and commercial launch in November 2026, with the first batch of patients now benefiting from treatment.

- Advertisement -

Product & Access Timeline

ItemDetail
ProductAjovy (fremanezumab injection)
ClassCGRP‑targeted monoclonal antibody therapy
IndicationPreventive treatment of migraine
OriginatorTeva Pharmaceutical – independently developed
2023Approved by the Guangdong Provincial Medical Products Administration; introduced into the Greater Bay Area
April 2026NeuroGen Pharma enters strategic collaboration with Teva; obtains exclusive mainland China commercialization rights
June 2026Approved by the National Medical Products Administration (NMPA) for preventive treatment of migraine in adults
November 2026Included in the NRDL following negotiations; commercial launch achieved – first batch of patients treated
18 Nov 2026Commencement of clinical supply announced

Drug Profile & Dosing Regimen

  • Molecule: Fremanezumab, a CGRP‑targeted biologic that blocks the calcitonin gene‑related peptide pathway – a key mediator of migraine pathophysiology.
  • Origin: Independently developed by Teva Pharmaceutical, an established global neuroscience franchise asset.
  • Dosing Flexibility: Two subcutaneous regimens – 225 mg once monthly and 675 mg once quarterly – offering patients and clinicians a choice between monthly and quarterly administration.
  • Administration Route: Subcutaneous injection supports at‑home or outpatient use, avoiding infusion‑based delivery.
  • Approved Population (Mainland China): Adults requiring preventive migraine treatment, per the June 2026 NMPA approval.

Commercialization Strategy & Market Access

  • Exclusive Rights Model: Under the April 2026 strategic collaboration with Teva, NeuroGen Pharma holds exclusive rights to commercialize Ajovy in mainland China, pairing an originator asset with a local launch engine.
  • Regulatory Pathway: The product followed a distinctive two‑stage access route – early regional entry via Guangdong Provincial MPA approval (2023) under the Greater Bay Area policy framework, then full national approval via the NMPA (June 2026).
  • Reimbursement Secured: Inclusion in the NRDL following negotiations (November 2026) removes the principal out‑of‑pocket barrier for chronic preventive therapy – a decisive factor for patient uptake in migraine prevention.
  • Launch Execution: Commercial launch achieved with the first batch of patients treated; the commencement of clinical supply marks the transition from approval to steady‑state market servicing. Negotiated NRDL price, launch sequencing by city tier, and channel structure were not disclosed.

Market Impact & Outlook

  • Migraine Landscape: Migraine affects a large adult population in China, yet CGRP‑targeted preventive therapies remain an early‑penetration category – positioning first movers with NRDL coverage for meaningful share capture.
  • Competitive Edge: Ajovy’s dual monthly/quarterly subcutaneous regimens differentiate on convenience within the CGRP class, where dosing frequency and route drive adherence in chronic prevention.
  • Speed to Market: From exclusive licensing (April 2026) to national approval (June 2026) to reimbursed launch (November 2026), the compressed timeline demonstrates an efficient originator–local‑partner commercialization model.
  • Strategic Signal for Teva: The collaboration extends Teva’s Ajovy footprint into mainland China without direct commercial infrastructure, leveraging NeuroGen’s local access capabilities.
  • Watchpoints: NRDL volume‑price dynamics, competitive entries in the CGRP class, physician and patient education on preventive‑therapy value, and real‑world uptake across city tiers; sales guidance was not disclosed.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization, supply, and market uptake of Ajovy (fremanezumab injection) in mainland China. Actual results may differ due to risks including NRDL pricing and reimbursement dynamics, competitive entries in the CGRP‑targeted class, supply chain execution, regulatory changes, and the pace of physician and patient adoption.-Fineline Info & Tech

Share This Article
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *